HSK39297 200mgQD

DRUG3 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

IgA Nephropathy (IgAN)Lupus Nephritis (LN)

Phase 2

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

CompletedNCT06670352

Haisco Pharmaceutical Group Co., Ltd.IgA Nephropathy (IgAN)

Start: 2024-10-12End: 2026-05-15Updated: 2026-05-28

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

RecruitingNCT07363460

Haisco Pharmaceutical Group Co., Ltd.Lupus Nephritis (LN)

Start: 2025-11-18End: 2028-07-06Target: 105Updated: 2026-01-23

A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy

RecruitingNCT07616700

Haisco Pharmaceutical Group Co., Ltd.IgA Nephropathy (IgAN)

Start: 2025-08-25End: 2026-12-26Target: 73Updated: 2026-06-01